Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
a study on Inflammatory Bowel Disease
The purpose of the trial is to determine the long-term safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials will have the option to enroll in this trial to receive study medication for up to 5 years or until marketed approval
Ulcerative Colitis Colitis Ulcer Colitis, Ulcerative RPC1063 RPC0163 (Ozanimod)
You can join if…
Open to people ages 18 years and up
- Previously participated in a trial of RPC1063 for UC and meet the criteria for participation in the open label extension as outlined in the prior trial
- Female patients of childbearing potential:
Must agree to practice a highly effective method of contraception throughout the trial until completion of the safety follow-up visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly. Acceptable methods of birth control in the trial are the following:
- combined hormonal (oestrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal
- progestogen-only hormonal contraception associated with inhibition of ovula-tion,which may be oral, injectable, or implantable
- placement of an intrauterine device (IUD)
- placement of an intrauterine hormone-releasing system (IUS)
- bilateral tubal occlusion
- vasectomised partner
- sexual abstinence
Must agree to use a latex condom during sexual contact with women of childbearing po-tential while participating in the trial until completion of the safety follow-up visit.
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal(coitus interruptus), spermicides only, and lactational amenorrhoea method are not ac-ceptable methods of contraception. Female condom and male condom should not be used together.
- Must provide written informed consent and have the ability to be compliant with the schedule of protocol assessments, which must be obtained prior to any trial-related procedures.
You CAN'T join if...
- Have received any of the following therapies since the first dose of investigational drug in the prior RPC1063 trial:
- Treatment with a biologic agent
- Treatment with an investigational agent other than RPC1063
- Treatment with D-penicillamine, leflunomide, thalidomide, natalizumab or fingolimod
- Treatment with lymphocyte-depleting therapies (e.g., Campath, anti-CD4,cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, alemtuzumab, daclizumab)
- Treatment with a live vaccine within 4 weeks prior to Visit 1 of this trial
- Are currently receiving or require initiation of any of the following therapies:
- Treatment with corticosteroids at a dose that exceeds the prednisone equivalent of >40 mg
- Treatment with immunosuppressive agents (eg, azathioprine, 6-MP, or methotrexate)
- Chronic non-steroidal anti-inflammatory drug (NSAID) use (Note: occasional use of NSAIDs and acetaminophen [eg, headache, arthritis, myalgias, or menstru-al cramps] and aspirin up to 325 mg/day is permitted)
- Treatment with Class Ia or Class III anti-arrhythmic drugs or treatment with two or more agents in combination known to prolong PR interval
- Pregnancy, lactation, or a positive serum beta human chorionic gonadotropin (hCG)
- Clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine,psychiatric or other major systemic disease making implementation of the protocol or interpretation of the trial difficult or that would put the patient at risk by participating in the trial or that would have required a patient to discontinue treatment in previous RPC1063 trial
- Clinically relevant cardiovascular conditions, including history or presence of recent myocardial infarction, unstable angina, stroke, transient ischemic attack,decompensated heart failure requiring hospitalization, Class III/IV heart failure,sick sinus syndrome, or severe untreated sleep apnea
- Liver function impairment or persisting elevations of aspartate aminotransferase (AST)or alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN), or direct bilirubin > 3 times the ULN
- FEV1 or FVC < 50% of predicted values
- University of California at San Francisco (PARENT) accepting new patients
San Francisco California 94115 United States
- OM Research accepting new patients
Lancaster California 93534 United States
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02531126.